Abstract:Background Schitosomiasis japonica is still a significant public health problem in China. A protective vaccine for human or animal use represents an important strategy for long-term control of this disease. Due to the complex life cycle of schistosomes, different vaccine design approaches may be necessary, including polyvalent subunit vaccines. In this study, we constructed four chimeric proteins (designated SjGP-1~4) via fusion of Sj26GST and four individual paramyosin fragments. We tested these four proteins as vaccine candidates, and investigated the effect of deviating immune response on protection roles in mice. Methods The immunogencity and protection efficacy of chimeric proteins were evaluated in mice. Next, the chimeric protein SjGP-3 was selected and formulated in various adjuvants, including CFA, ISA 206, IMS 1312 and ISA 70M. The titers of antigen-specific IgG, IgE and IgG subclass were measured. The effect of adjuvant on cytokine production and percentages of CD3 + CD8 - IFN-γ + cells and CD3 + CD8 - IL-4 + cells were analyzed at different time points. Worm burdens and liver egg counts in different adjuvant groups were counted to evaluate the protection efficacy against cercarial challenge. Results Immunization of mice with chimeric proteins provided various levels of protection. Among the four proteins, SjGP-3 induced the highest level of protection, and showed enhanced protective efficacy compared with its individual component Sj26GST. Because of this, SjGP-3 was further formulated in various adjuvants to investigate the effect of adjuvant on immune deviation. The results revealed that SjGP-3 formulated in veterinary adjuvant ISA 70M induced a lasting polarized Th1 immune response, whereas the other adjuvants, including CFA, ISA 206 and IMS 1312, generated a moderate mixed Th1/Th2 response after immunization but all except for IMS 1312 shifted to Th2 response after onset of eggs. More importantly, the SjGP-3/70M formulation induced a significant reduction in liver egg deposition at 47.0–50.3% and the number of liver eggs per female at 34.5–37.2% but less effect on worm burdens at only 17.3–23.1%, whereas no effect of the formulations with other adjuvants on the number of liver eggs per female was observed. Conclusion Construction of polyvalent subunit vaccine was capable to enhance immunogenicity and protection efficacy against schistosomiasis. There was correlation of the polarized Th1 response with reduction of liver egg burdens, supporting the immune deviation strategy for schistosomiasis japonica vaccine development.

Comparative efficacy of Schistosoma japonicum bivalent DNA vaccines constructed in multimode

[Construction and Expression of Schistosoma Japonicum Bivalent DNA Vaccines and Their Efficiencies of Protective Immunity].

Studies on the Protective Immunity of Schistosoma Japonicum Bivalent DNA Vaccine Encoding Sj23 and Sj14.

Schistosoma japonicum : The design and experimental evaluation of a multivalent DNA vaccine

Construction of the Bivalent Vaccine Pvax1/sjrps4.cb, Pcdna3.0/sjrps4.cb Against Female Fecundity of Schistosoma Japonicum and Its Immunoprotection Effect.

Construction, purification, and evaluation of multivalent DNA vaccine against Schistosoma japonicum

Construction and Immunoprotection of Schistosoma Japonicum Muitivalent DNA Vaccine in Mice

[A multi-gene DNA vaccine encoding non-fusion membrane-anchoring antigen against Schistosoma japonicum]

Combined Immunoprotection of Schistosoma Japonicum Ribosomal Protein S4 Gene and Recombinant Protein

The Immunogenicity of CO-expressing Plasmid and Fusion Genes Plasmid Containing IBDV VP2/4/3 and ChIL-18 Genes

DNA Vaccine Encoding SjIR3 Induces Partial Immune Protection Against Schistosoma Japonicum in Mice

[Protective Efficacy of Co-Immunization with Sj26 DNA and Recombinant Protein Vaccine Against Schistosoma Japonicum in Mice].

Construction and Immuno-protection Evaluation of Trivalent-epitope DNA Vaccine Pvivo2-Sjfabp/sj26. SjGAPDH

Preliminary studies on the expression of bivalent DNA vaccine against Schistosoma japonicum in vitro/vivo and lasting time

A Schistosoma Japonicum Chimeric Protein with A Novel Adjuvant Induced A Polarized Th1 Immune Response and Protection Against Liver Egg Burdens

Acute toxicity test of Schistosoma japonicum bivalent DNA vaccine with single dosage in mice

Construction of a Novel Schistosoma Japonicum DNA Vaccine Pbk-Sj14-3-3 and Studies on Its Immunoprotection in Mice

Protective Effect Induced by Vaccination with a Partial cDNA Expression Library of Schistosoma japonicum in Mice

The Immunoprotective Effect of Co-inoculation of Schistosoma Japonicum Fatty Acid Binding Protein (sj14fabp)dna and IL-12 in the Mouse

Generation of the Antibody Against the Schistosoma Japonicum Antigen Sj22 with Genetic Immunization

Study of Two Candidates of Schistosoma japonicum Vaccine